# Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

> **NCT03704688** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- KRAS Gene Mutation

## Interventions

- **DRUG:** Trametinib 0.5 mg
- **DRUG:** Trametinib 1 MG
- **DRUG:** Trametinib 1.5 MG
- **DRUG:** Trametinib 2 mg
- **DRUG:** Ponatinib 15 MG
- **DRUG:** Ponatinib 30 MG

## Key facts

- **NCT ID:** NCT03704688
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03704688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03704688, "Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03704688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*